Skip to main content

Artelo Biosciences, Inc. (ARTL)

NASDAQ: ARTL · IEX Real-Time Price · USD
0.850 0.043 (5.35%)
Sep 17, 2021 4:00 PM EDT - Market closed
Market Cap20.82M
Revenue (ttm)n/a
Net Income (ttm)-6.58M
Shares Out24.49M
EPS (ttm)-0.48
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume335,413
Open0.844
Previous Close0.807
Day's Range0.821 - 0.860
52-Week Range0.451 - 3.670
Beta1.36
AnalystsBuy
Price Target6.00 (+605.9%)
Est. Earnings Daten/a

About ARTL

Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing treatments to modulate the endocannabinoid system. Its product candidate pipeline includes ART27.13, a synthetic G protein-coupled receptor agonist, which is in Phase 1 clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment of inflammatory bowel disease and post-traumatic stress disorder (PTSD); and ART26.12, a fatty acid binding protein 5 inhibitor for prosta...

IndustryPharmaceuticals
Founded2011
Employees4
Stock ExchangeNASDAQ
Ticker SymbolARTL
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to one analyst, the rating for ARTL stock is "Buy" and the 12-month stock price forecast is 6.00.

Price Target
$6.00
(605.88% upside)
Analyst Consensus: Buy

News

Artelo Biosciences to Present at the Q3 Virtual Investor Summit on August 18th

Solana Beach, California--(Newsfile Corp. - August 11, 2021) - Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company focused on the development of therapeutics that target ...

1 month ago - Newsfile Corp

Artelo Biosciences Announces Publication of Study Results Comparing the Pharmacological Effects of Plant-Derived Vers...

Study finds no in-vitro pharmacological difference in the antiproliferative, anti-inflammatory, or permeability effects of purified natural versus synthetic CBD

1 month ago - GlobeNewsWire

Ladenburg Thalmann to Host R&D Showcase Featuring Artelo Biosciences' CAReS Study on July 28, 2021

LA JOLLA, Calif., July 21, 2021 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ: ARTL ), a clinical stage biopharmaceutical company focused on the development of therapeutics that target lipid sign...

1 month ago - GlobeNewsWire

Artelo Biosciences Reports Third Quarter Fiscal 2021 Financial Results and Provides Business Update

Enrollment in CAReS Study in patients with cancer anorexia on track to deliver first data readout by calendar year-end

2 months ago - GlobeNewsWire

Artelo Biosciences Announces Two Poster Presentations Featured at the 31st Annual ICRS Symposium

Dr. Andrew Yates to Present Poster on the Company's ART27.13 Cancer Appetite Recovery Study

2 months ago - GlobeNewsWire

Artelo Biosciences to Present at the LD Micro Virtual Invitational XI on June 9th

LA JOLLA, Calif., June 02, 2021 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ: ARTL ), a clinical stage biopharmaceutical company focused on the development of therapeutics that modulate endogeno...

3 months ago - GlobeNewsWire

Artelo Biosciences Reports Second Quarter Fiscal 2021 Financial Results and Provides Business Update

Recently Commenced Patient Enrollment in Phase 1/2 CAReS Study of ART27.13 in the UK

5 months ago - GlobeNewsWire

Artelo Biosciences Doses First Patient in CAReS Study with ART27.13 for the Treatment of Cancer-Related Anorexia and ...

Initial safety data expected from CAReS Study before end of 2021

5 months ago - GlobeNewsWire

Artelo Biosciences Accepted into the Alderley Park Oncology Development Program for FABP5 Inhibitor Biomarker Develop...

Detection of elevated FABP5 associated with additional tumor types suggests  the target for ART26.12 may be more broadly relevant in cancer therapy

6 months ago - GlobeNewsWire

Artelo Biosciences, Inc. to Present at the Q1 Virtual Investor Summit on March 23rd

LA JOLLA, Calif., March 11, 2021 (GLOBE NEWSWIRE) -- via InvestorWire – Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company developing therapeutics that modulate lipid-si...

6 months ago - GlobeNewsWire

Artelo Biosciences Appoints Finance and Healthcare Industry Executive Tamara A. Seymour to Board of Directors

LA JOLLA, Calif., March 09, 2021 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ: ARTL ), a clinical stage biopharmaceutical company focused on the development of therapeutics that target lipid-sig...

6 months ago - GlobeNewsWire

Artelo Biosciences to Present at the H.C. Wainwright Global Life Sciences Conference on March 9th

LA JOLLA, Calif., March 02, 2021 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company developing therapeutics that modulate endogenous signaling pathwa...

6 months ago - GlobeNewsWire

Artelo Biosciences Announces Positive Pre-Clinical Data Associated with Proprietary CBD Cocrystal

Research demonstrates co-administration of CBD and TMP could confer ART12.11 with a more desirable pharmacodynamic profile Research demonstrates co-administration of CBD and TMP could confer ART12.11 wi...

7 months ago - GlobeNewsWire

ARTL Stock Alert: The Big Reason Biopharma Artelo Biosciences Is Rocketing Today

Artelo Biosciences (ARTL) stock is soaring higher on Friday after Ladenburg analyst Michael Higgins initiated coverage of the company. The post ARTL Stock Alert: The Big Reason Biopharma Artelo Bioscien...

7 months ago - InvestorPlace

Artelo Biosciences Receives $3.0 Million in Net Proceeds from Exercise of Warrants

LA JOLLA, Calif., Feb. 08, 2021 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company developing therapeutics that modulate endogenous signaling pathway...

7 months ago - GlobeNewsWire

Artelo Biosciences Announces Research Collaboration with Trinity College Dublin to Investigate ART27.13 for the Treat...

LA JOLLA, Calif., Feb. 02, 2021 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc.  (NASDAQ:  ARTL ) today embarks on a collaboration with researchers from Trinity College Dublin to investigate pre-clinical m...

7 months ago - GlobeNewsWire

Artelo Biosciences to Present at the LSX World Congress Virtual Conference

LA JOLLA, Calif., Jan. 29, 2021 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company developing therapeutics that modulate endogenous signaling pathway...

7 months ago - GlobeNewsWire

Artelo Biosciences Reports First Quarter Fiscal Year 2021 Financial Results and Provides Business Update

Received Clinical Trial Authorization to Commence Cancer Appetite Recovery Phase I/II Clinical Study of ART27.13 in UK

8 months ago - GlobeNewsWire

Artelo Biosciences to Present at the H.C. Wainwright BioConnect 2021 Conference

LA JOLLA, Calif., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company developing therapeutics that modulate the endocannabinoid system, ...

8 months ago - GlobeNewsWire

Artelo Biosciences Files Patent Application for New Formulation of ART27.13

Expanding the patent estate for the lead clinical program to treat cancer anorexia Expanding the patent estate for the lead clinical program to treat cancer anorexia

9 months ago - GlobeNewsWire

Artelo Biosciences to Present at The 13th Annual LD Micro Main Event Conference on December 15th

LA JOLLA, Calif., Dec. 08, 2020 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc.  (NASDAQ:  ARTL ), a clinical stage biopharmaceutical company focused on the development of therapeutics that modulate endoge...

9 months ago - GlobeNewsWire

Artelo Biosciences Announces Appointment of Senior Pharmaceutical Executive Gregory R. Reyes, M.D.

LA JOLLA, Calif., Dec. 02, 2020 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc.  (NASDAQ:  ARTL ), a clinical stage biopharmaceutical company focused on the development of therapeutics that modulate endoge...

9 months ago - GlobeNewsWire

Artelo Biosciences and University of Western Ontario Awarded Research Grant by Mitacs

Mitacs Accelerate grant expected to fund 50% of research costs evaluating ART26.12 as a potential treatment for anxiety disorders Mitacs Accelerate grant expected to fund 50% of research costs evaluatin...

9 months ago - GlobeNewsWire

Artelo Biosciences Reports Fourth Quarter and Fiscal 2020 Year-End Financial Results and Provides Business Update

LA JOLLA, Calif., Nov. 04, 2020 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company focused on the development of therapeutics that modulate endogenou...

10 months ago - GlobeNewsWire